Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 2/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25241808 | 0.91 | ROCK1 (0.37) | ROCK1RAB9ACXCR2KLKB1P2RX7 | |
| SCHEMBL23303824 | 0.87 | P2RX7 (0.34) | ROCK1CXCR2KLKB1P2RX7 | |
| SCHEMBL22664611 | 0.85 | PRMT5 (0.45) | CA1CA2CA9 | |
| SCHEMBL25832761 | 0.83 | JAK2 (0.34) | ROCK1CXCR2JAK2BTKLIPG | |
| SCHEMBL29710536 | 0.80 | HPGD (0.52) | NPC1P2RX7KDM4E | |
| SCHEMBL20472661 | 0.79 | CXCR2 (0.48) | ROCK1CXCR2P2RX7LIPG | |
| SCHEMBL25209501 | 0.78 | P2RX7 (0.38) | ROCK1CXCR2P2RX7CA1CA2 | |
| SCHEMBL24802261 | 0.78 | BTK (0.43) | BTKKDM4E | |
| SCHEMBL23304093 | 0.78 | ROCK1 (0.33) | ROCK1P2RX7CA1CA2CA9 | |
| SCHEMBL20839950 | 0.76 | CXCR2 (0.39) | ROCK1CXCR2P2RX7LIPEJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793994-B1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3793994-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ROCK1 450/4885RAB9A 2275/4885NPC1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.